RESEARCH-USE BIOSIMILAR ANTIBODY
Netakimab
Monoclonal antibody · IgG1
Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
Netakimab is a recombinant research-use antibody directed against IL17A.